Literature DB >> 25385317

Increased Igf-I/Igfbp-3 Ratios in Postmenopausal Taiwanese with Breast Cancer, Irrespective of Er and Pr Statuses and Her2 Expression in a Case-Control Study.

Su-Chen Lee1, Shih-Meng Tsai2, Ming-Feng Hou3, Li-Ying Tien4, Szu-Hsien Wu5, Lisa Ann Hou6, Joseph M Tsai7, Li-Yu Tsai8.   

Abstract

BACKGROUND: In most research, there were positive associations between the insulin-like growth factor I (IGF-I) status, including IGF-I, insulin-like growth factor binding protein-3 (IGFBP-3), and ratio of IGF-I/IGFBP-3, and risks of breast cancer (BC), which was influenced by many factors, including hormone statuses and ethnicity. Therefore, the alterations of the IGF-I status in Taiwanese women with BC by menopausal statuses and hormone receptors were investigated.
METHODS: The levels of IGF-I and IGFBP-3 were determined by the enzyme-labeled chemiluminescent immunometric assay, and the protein expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) on paraffin-embedded sections of tissues with BC were analyzed by the immunohistochemical method.
RESULTS: The ratios of IGF-I/IGFBP-3 were significantly higher in the women with BC than those in the controls, but not of the levels of IGF-I and IGFBP-3; furthermore, the significantly higher ratios were found only in the postmenopausal status. In addition, there was no significant difference between the IGF-I status and ER and PR statuses, and HER2 expression, respectively, in the women with BC.
CONCLUSIONS: The ratios of IGF-I/IGFBP-3 were increased in postmenopausal Taiwanese women with BC, irrespective of their ages, ER and PR statuses, and HER2 expression.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  IGF-I; IGF-I/IGFBP-3 ratio; IGFBP-3; breast cancer; menopausal status

Mesh:

Substances:

Year:  2014        PMID: 25385317      PMCID: PMC6807081          DOI: 10.1002/jcla.21815

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  40 in total

1.  Insulin-like growth factor-I and estrogen interactions in breast cancer.

Authors:  Mary Beth Martin; Adriana Stoica
Journal:  J Nutr       Date:  2002-12       Impact factor: 4.798

2.  Evaluation of the insulin-like growth factors (IGF) IGF-I and IGF binding protein 3 in patients at high risk for breast cancer.

Authors:  Angela F Trinconi; José Roberto Filassi; José Maria Soares; Edmund C Baracat
Journal:  Fertil Steril       Date:  2011-03-10       Impact factor: 7.329

3.  Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.

Authors:  Harriet Johansson; Laura Baglietto; Aliana Guerrieri-Gonzaga; Bernardo Bonanni; Frederique Mariette; Debora Macis; Davide Serrano; Maria Teresa Sandri; Andrea Decensi
Journal:  Breast Cancer Res Treat       Date:  2004-11       Impact factor: 4.872

4.  Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status.

Authors:  Benjamin B E Barnes; Jenny Chang-Claude; Dieter Flesch-Janys; Ralf Kinscherf; Martina Schmidt; Tracy Slanger; Gabriel Bonaterra; Karen Steindorf
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

5.  Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women.

Authors:  Nicole M Probst-Hensch; Hao Wang; Victor H H Goh; Adeline Seow; Hin-Peng Lee; Mimi C Yu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-08       Impact factor: 4.254

6.  Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature.

Authors:  Aravind Sugumar; Yen-Chun Liu; Qiang Xia; Yea-Suk Koh; Keitaro Matsuo
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

7.  Divergent effects of short-term, very-low-calorie diet on insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum concentrations in premenopausal women with obesity.

Authors:  G De Pergola; M Zamboni; N Pannacciulli; E Turcato; F Giorgino; F Armellini; F Logoluso; M Sciaraffia; O Bosello; R Giorgino
Journal:  Obes Res       Date:  1998-11

8.  Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3.

Authors:  Jay H Fowke; Charles E Matthews; Herbert Yu; Qiuyin Cai; Sarah Cohen; Maciej S Buchowski; Wei Zheng; William J Blot
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

9.  Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor I in vitro.

Authors:  Anke Schlenska-Lange; Heike Knüpfer; Tobias J Lange; Wieland Kiess; Matthias Knüpfer
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

10.  Relationships between critical period of estrogen exposure and circulating levels of insulin-like growth factor-I (IGF-I) in breast cancer: evidence from a case-control study.

Authors:  Mei-Hsuan Wu; Yu-Ching Chou; Wan-Yun Chou; Giu-Cheng Hsu; Chi-Hong Chu; Cheng-Ping Yu; Jyh-Cherng Yu; Chien-An Sun
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

View more
  2 in total

1.  Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer.

Authors:  K D Crew; T Xiao; P S Thomas; M B Terry; M Maurer; K Kalinsky; S Feldman; L Brafman; S R Refice; D L Hershman
Journal:  Int J Food Sci Nutr Diet       Date:  2015-02-23

2.  Insulin-like growth factor-1 positively associated with bone formation markers and creatine kinase in adults with general physical activity.

Authors:  Su-Chen Lee; Jen-Kuei Hsiao; Yu-Chun Yang; Jung-Chih Haung; Li-Ying Tien; Dai-En Li; Shih-Meng Tsai
Journal:  J Clin Lab Anal       Date:  2021-06-18       Impact factor: 2.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.